Product name:Triethyl citrate
CAS:77-93-0
Molecular Formula:C12H2OO7
Molecular Weight: 276.32
Product description:Colorless to pale yellow liquid, there is wine, fruit and melon aromas, used to flavor, edible flavor, modulation of grapes, pears and other scent flavor.
Product name:Triflusal
CAS: 322-79-2
Molecular Formula: C10H7F3O4
Molecular Weight: 248.16
Product description:The drug by the irreversible inhibition of the platelet epoxy synthase is reduce the biological form thrombus, its main metabolites HTB (3 - hydroxy - 4-3 acid) is an enzyme called cyclooxygenase platelet reversible inhibitor, and its half-life is very long (about 34 hours), it is advantageous to the willow three fluorine antiplatelet activity; HTB and metabolites can inhibit platelet phosphodiesterase increased platelet inside the cAMP, the content, resulting in platelet aggregation. Against the role of endothelial cell ring oxidase minimal, does not affect the synthesis of prostaglandins, and its metabolites can increase the platelet coagulation effect, the drug used in the human body does not increase the bleeding time, clinical trials to confirm if the thrombolysis therapy used at the same time, also do not increase the incidence of cardiovascular hemorrhage, the unstable angina pectoris, coronary artery molding and short circuit, the procedure for acute myocardial infarction (mi), the validity of thromboembolic disease and peripheral vascular disease and aspirin are the same, but very little bleeding complications, used for cerebrovascular disease secondary beforehand
CAS: 322-79-2
Molecular Formula: C10H7F3O4
Molecular Weight: 248.16
Product description:The drug by the irreversible inhibition of the platelet epoxy synthase is reduce the biological form thrombus, its main metabolites HTB (3 - hydroxy - 4-3 acid) is an enzyme called cyclooxygenase platelet reversible inhibitor, and its half-life is very long (about 34 hours), it is advantageous to the willow three fluorine antiplatelet activity; HTB and metabolites can inhibit platelet phosphodiesterase increased platelet inside the cAMP, the content, resulting in platelet aggregation. Against the role of endothelial cell ring oxidase minimal, does not affect the synthesis of prostaglandins, and its metabolites can increase the platelet coagulation effect, the drug used in the human body does not increase the bleeding time, clinical trials to confirm if the thrombolysis therapy used at the same time, also do not increase the incidence of cardiovascular hemorrhage, the unstable angina pectoris, coronary artery molding and short circuit, the procedure for acute myocardial infarction (mi), the validity of thromboembolic disease and peripheral vascular disease and aspirin are the same, but very little bleeding complications, used for cerebrovascular disease secondary beforehand